Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||KIT positive|
|Gene Variant Detail|
|Relevant Treatment Approaches||KIT Inhibitor|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT positive||germ cell cancer||resistant||KIT Inhibitor||Imatinib||Phase II||Actionable||In a small Phase II study, 18 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496).||16462496|
|KIT positive||gastrointestinal stromal tumor||sensitive||KIT Inhibitor||Imatinib||FDA approved||Actionable||In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in an overall response rate of 38% (56/147) and a median duration of response of 13 weeks in patients with metastatic or unresectable KIT-positive GIST (PMID: 12374669).||12374669 detail...|
|KIT positive||prostate neuroendocrine neoplasm||no benefit||KIT Inhibitor||Imatinib||Preclinical||Actionable||In a preclinical study, a prostate neuroendocrine tumor mouse model expressing Kit did not respond to Gleevec (imatinib), a result of impaired signaling of the Kit pathway (PMID: 27980106).||27980106|
|KIT positive||breast cancer||predicted - sensitive||KIT Inhibitor||Imatinib + Letrozole||Phase 0||Actionable||In a pilot trial, Gleevec (imatinib mesylate) and Femara (letrozole) combination treatment resulted in clinical partial response in 90% (9/10) and stable disease in 10% (1/10) of the evaluable patients with invasive hormone-sensitive breast cancer, 8 of the 13 enrolled patients had KIT-positive tumors (PMID: 18248884).||18248884|